Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Trends in Cannabis Treatment Admissions in Adolescents/Young Adults: Analysis of TEDS-A 1992 to 2016.

Standeven LR, Scialli A, Chisolm MS, Terplan M.

J Addict Med. 2020 Jan 24. doi: 10.1097/ADM.0000000000000586. [Epub ahead of print]

PMID:
31985511
2.

Sexual and Reproductive Health Characteristics of Women in Substance Use Treatment in Michigan.

MacAfee LK, Harfmann RF, Cannon LM, Kolenic G, Kusunoki Y, Terplan M, Dalton VK.

Obstet Gynecol. 2020 Feb;135(2):361-369. doi: 10.1097/AOG.0000000000003666.

PMID:
31923070
3.

Unmet substance use disorder treatment need among reproductive age women.

Martin CE, Scialli A, Terplan M.

Drug Alcohol Depend. 2020 Jan 1;206:107679. doi: 10.1016/j.drugalcdep.2019.107679. Epub 2019 Oct 28.

PMID:
31740208
4.

Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.

Nielsen T, Bernson D, Terplan M, Wakeman SE, Yule AM, Mehta PK, Bharel M, Diop H, Taveras EM, Wilens TE, Schiff DM.

Addiction. 2020 Feb;115(2):291-301. doi: 10.1111/add.14825. Epub 2019 Nov 13.

PMID:
31692133
5.

Obstetrician-gynecologists' practices and attitudes on substance use screening during pregnancy.

Ko JY, Tong VT, Haight SC, Terplan M, Stark L, Snead C, Schulkin J.

J Perinatol. 2019 Oct 30. doi: 10.1038/s41372-019-0542-3. [Epub ahead of print]

PMID:
31666646
6.

Pain, Opioids, and Pregnancy: Historical Context and Medical Management.

Martin CE, Terplan M, Krans EE.

Clin Perinatol. 2019 Dec;46(4):833-847. doi: 10.1016/j.clp.2019.08.013. Epub 2019 Aug 22. Review.

PMID:
31653311
7.

Chlamydia in adolescent/adult reproductive management trial study (CHARM): Clinical core protocol.

Mark KS, Brotman RM, Martinez-Greiwe S, Terplan M, Bavoil P, Ravel J.

Contemp Clin Trials Commun. 2019 Jul 19;16:100414. doi: 10.1016/j.conctc.2019.100414. eCollection 2019 Dec.

8.

Obstetrician-gynecologists' practice patterns related to opioid use during pregnancy and postpartum-United States, 2017.

Ko JY, Tong VT, Haight SC, Terplan M, Snead C, Schulkin J.

J Perinatol. 2019 Oct 15. doi: 10.1038/s41372-019-0535-2. [Epub ahead of print]

PMID:
31616051
9.

Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.

Premkumar A, Grobman WA, Terplan M, Miller ES.

Obstet Gynecol. 2019 Nov;134(5):921-931. doi: 10.1097/AOG.0000000000003503.

PMID:
31599845
10.

Nonoptimal Vaginal Microbiota After Azithromycin Treatment for Chlamydia trachomatis Infection.

Tamarelle J, Ma B, Gajer P, Humphrys MS, Terplan M, Mark KS, Thiébaut ACM, Forney LJ, Brotman RM, Delarocque-Astagneau E, Bavoil PM, Ravel J.

J Infect Dis. 2020 Feb 3;221(4):627-635. doi: 10.1093/infdis/jiz499.

PMID:
31573603
11.

RE: Expanding Contraceptive Access for Women With Substance Use Disorders: Partnerships Between Public Health Departments and County Jails.

Sufrin C, Terplan M, Scott C, Roberts S.

J Public Health Manag Pract. 2019 Nov/Dec;25(6):E10-E11. doi: 10.1097/PHH.0000000000001078. No abstract available.

PMID:
31569194
12.

Cingulo-hippocampal effective connectivity positively correlates with drug-cue attentional bias in opioid use disorder.

Ma L, Steinberg JL, Bjork JM, Taylor BA, Arias AJ, Terplan M, Anastasio NC, Zuniga EA, Lennon M, Cunningham KA, Moeller FG.

Psychiatry Res Neuroimaging. 2019 Dec 30;294. pii: S0925-4927(19)30026-5. doi: 10.1016/j.pscychresns.2019.08.005. Epub 2019 Aug 13.

PMID:
31439409
13.

The Cervicovaginal Microbiota-Host Interaction Modulates Chlamydia trachomatis Infection.

Edwards VL, Smith SB, McComb EJ, Tamarelle J, Ma B, Humphrys MS, Gajer P, Gwilliam K, Schaefer AM, Lai SK, Terplan M, Mark KS, Brotman RM, Forney LJ, Bavoil PM, Ravel J.

mBio. 2019 Aug 13;10(4). pii: e01548-19. doi: 10.1128/mBio.01548-19.

14.

Cognitive and Behavioral Impact on Children Exposed to Opioids During Pregnancy.

Larson JJ, Graham DL, Singer LT, Beckwith AM, Terplan M, Davis JM, Martinez J, Bada HS.

Pediatrics. 2019 Aug;144(2). pii: e20190514. doi: 10.1542/peds.2019-0514. Epub 2019 Jul 18. Review.

PMID:
31320466
15.

National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder.

Krans EE, Campopiano M, Cleveland LM, Goodman D, Kilday D, Kendig S, Leffert LR, Main EK, Mitchell KT, OʼGurek DT, DʼOria R, McDaniel D, Terplan M.

Obstet Gynecol. 2019 Aug;134(2):365-375. doi: 10.1097/AOG.0000000000003381.

PMID:
31306323
16.

Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer.

Rubinsak LA, Terplan M, Martin CE, Fields EC, McGuire WP, Temkin SM.

Gynecol Oncol Rep. 2019 Mar 27;28:116-119. doi: 10.1016/j.gore.2019.03.016. eCollection 2019 May.

17.

Rates of and Factors Associated With Patient-reported Illicit Drug Use Screening by Health Care Professionals in the United States From 2013 to 2015.

Scialli AC, Terplan M.

J Addict Med. 2020 Jan/Feb;14(1):63-68. doi: 10.1097/ADM.0000000000000537.

PMID:
30946091
18.

Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.

Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, Blake-Lamb T, Guille C, Landau R, Minkoff H, Prabhu M, Rosenthal E, Terplan M, Wright TE, Yonkers KA.

Am J Obstet Gynecol. 2019 Jul;221(1):B5-B28. doi: 10.1016/j.ajog.2019.03.022. Epub 2019 Mar 27. No abstract available.

PMID:
30928567
19.

Screening for substance use in pregnancy and the newborn.

Polak K, Kelpin S, Terplan M.

Semin Fetal Neonatal Med. 2019 Apr;24(2):90-94. doi: 10.1016/j.siny.2019.01.007. Epub 2019 Feb 5. Review.

PMID:
30770326
20.

Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder.

Peeler M, Fiscella K, Terplan M, Sufrin C.

J Correct Health Care. 2019 Jan;25(1):4-14. doi: 10.1177/1078345818819855. Epub 2019 Jan 7.

21.

Contraceptive utilization among new exotic dancers: a cross-sectional study.

Terplan M, Martin CE, Nail J, Sherman SG.

Harm Reduct J. 2018 Nov 12;15(1):56. doi: 10.1186/s12954-018-0261-7.

22.

Pregnancy Intention, Risk Perception, and Contraceptive Use in Pregnant Women Who Use Drugs.

MacAfee LK, Dalton V, Terplan M.

J Addict Med. 2019 May/Jun;13(3):177-181. doi: 10.1097/ADM.0000000000000471.

PMID:
30394994
23.

Racial and Ethnic Disparities in the Incidence of Severe Maternal Morbidity in the United States, 2012-2015.

Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK.

Obstet Gynecol. 2018 Nov;132(5):1158-1166. doi: 10.1097/AOG.0000000000002937.

PMID:
30303912
24.

In Reply.

Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, Meyer MC, Jones HE, Krans EE.

Obstet Gynecol. 2018 Oct;132(4):1061-1062. doi: 10.1097/AOG.0000000000002885. No abstract available.

PMID:
30247340
25.

Pregnancy and Naltrexone Pharmacotherapy.

Jones CW, Terplan M.

Obstet Gynecol. 2018 Oct;132(4):923-925. doi: 10.1097/AOG.0000000000002864.

PMID:
30204703
26.

Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.

Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, Bharel M, Wilens TE, LaRochelle M, Walley AY, Land T.

Obstet Gynecol. 2018 Aug;132(2):466-474. doi: 10.1097/AOG.0000000000002734.

27.

Pregnancy intention and opioid use disorder treatment retention in the MOTHER study.

Martin CE, Terplan M, O'Grady KE, Jones HE.

Am J Addict. 2018 Jul 11. doi: 10.1111/ajad.12735. [Epub ahead of print]

PMID:
29995313
28.

Characteristics of Pregnant Women Reporting Cannabis Use Disorder at Substance Use Treatment Entry.

Washio Y, Mark K, Terplan M.

J Addict Med. 2018 Sep/Oct;12(5):395-400. doi: 10.1097/ADM.0000000000000424.

PMID:
29864087
29.

Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.

Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M.

J Subst Abuse Treat. 2018 Jun;89:67-74. doi: 10.1016/j.jsat.2018.04.003. Epub 2018 Apr 6.

PMID:
29706175
30.

Opioid Detoxification During Pregnancy: A Systematic Review.

Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, Meyer MC, Jones HE, Krans EE.

Obstet Gynecol. 2018 May;131(5):803-814. doi: 10.1097/AOG.0000000000002562.

31.

The Comprehensive Addiction and Recovery Act: Opioid Use Disorder and Midwifery Practice.

Murphy J, Goodman D, Johnson MC, Terplan M.

Obstet Gynecol. 2018 Mar;131(3):542-544. doi: 10.1097/AOG.0000000000002493.

PMID:
29420414
32.

Maternal Health in the United States.

Schiff DM, Patrick SW, Terplan M.

N Engl J Med. 2018 Feb 8;378(6):587. doi: 10.1056/NEJMc1715957. No abstract available.

PMID:
29419278
33.

A Pilot Randomized Controlled Trial of a Phone-based Intervention for Smoking Cessation and Relapse Prevention in the Postpartum Period.

Coleman-Cowger VH, Mark KS, Rosenberry ZR, Koszowski B, Terplan M.

J Addict Med. 2018 May/Jun;12(3):193-200. doi: 10.1097/ADM.0000000000000385.

34.

Risk of complication during surgical abortion in obese women.

Mark KS, Bragg B, Talaie T, Chawla K, Murphy L, Terplan M.

Am J Obstet Gynecol. 2018 Feb;218(2):238.e1-238.e5. doi: 10.1016/j.ajog.2017.10.018. Epub 2017 Oct 24.

PMID:
29074080
35.

Characteristics of pregnant women who reported alcohol use at admission to substance use treatment.

Washio Y, E Martin C, Goldstein ND, Terplan M.

J Subst Abuse Treat. 2017 Nov;82:82-86. doi: 10.1016/j.jsat.2017.09.010. Epub 2017 Sep 15.

PMID:
29021120
36.

Re: Neonatal Abstinence Syndrome and High School Performance.

Terplan M, Patrick S, Jansson LM.

Pediatrics. 2017 Jun;139(6). pii: e20170972A. doi: 10.1542/peds.2017-0972A. No abstract available.

37.

Women and the opioid crisis: historical context and public health solutions.

Terplan M.

Fertil Steril. 2017 Aug;108(2):195-199. doi: 10.1016/j.fertnstert.2017.06.007. Epub 2017 Jul 8. Review.

PMID:
28697909
38.

Cannabis and pregnancy: Maternal child health implications during a period of drug policy liberalization.

Mark K, Terplan M.

Prev Med. 2017 Nov;104:46-49. doi: 10.1016/j.ypmed.2017.05.012. Epub 2017 May 18.

PMID:
28528172
39.

Beyond the Treatment Box: Perspectives on the Federal Response to Opioid Use, Pregnancy, and Neonatal Abstinence Syndrome.

Terplan M.

J Addict Med. 2017 May/Jun;11(3):176-177. doi: 10.1097/ADM.0000000000000309.

PMID:
28406855
40.

Pregnant Women's Current and Intended Cannabis Use in Relation to Their Views Toward Legalization and Knowledge of Potential Harm.

Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M.

J Addict Med. 2017 May/Jun;11(3):211-216. doi: 10.1097/ADM.0000000000000299.

PMID:
28252456
41.

Opioid detoxification during pregnancy needs to be grounded in addiction science.

Terplan M.

Am J Obstet Gynecol. 2017 Jun;216(6):623. doi: 10.1016/j.ajog.2017.02.030. Epub 2017 Feb 22. No abstract available.

PMID:
28235462
42.

Medically Assisted Withdrawal (Detoxification): Considering the Mother-Infant Dyad.

Jones HE, Terplan M, Meyer M.

J Addict Med. 2017 Mar/Apr;11(2):90-92. doi: 10.1097/ADM.0000000000000289.

PMID:
28079573
43.

Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs.

Terplan M, Minkoff H.

Obstet Gynecol. 2017 Jan;129(1):164-167. doi: 10.1097/AOG.0000000000001781.

PMID:
27926654
44.

The role of screening, brief intervention, and referral to treatment in the perinatal period.

Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, Creanga AA.

Am J Obstet Gynecol. 2016 Nov;215(5):539-547. doi: 10.1016/j.ajog.2016.06.038. Epub 2016 Jul 1. Review.

PMID:
27373599
45.

Detoxification from opiates during pregnancy: stressing the fetal brain.

McCarthy JJ, Terplan M.

Am J Obstet Gynecol. 2016 Nov;215(5):670.e1-670.e2. doi: 10.1016/j.ajog.2016.05.041. Epub 2016 Jun 2. No abstract available.

PMID:
27262972
46.

Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic.

Premkumar A, Terplan M.

Obstet Gynecol. 2016 Nov;128(5):1179. No abstract available.

PMID:
27776054
47.

Family Planning in Substance Use Disorder Treatment Centers: Opportunities and Challenges.

Robinowitz N, Muqueeth S, Scheibler J, Salisbury-Afshar E, Terplan M.

Subst Use Misuse. 2016 Sep 18;51(11):1477-83. doi: 10.1080/10826084.2016.1188944. Epub 2016 Jul 20.

PMID:
27440391
48.

Breast Implants, Self-Esteem, Quality of Life, and the Risk of Suicide.

Zuckerman DM, Kennedy CE, Terplan M.

Womens Health Issues. 2016 Jul-Aug;26(4):361-5. doi: 10.1016/j.whi.2016.03.002. Epub 2016 Apr 16. No abstract available.

PMID:
27094911
49.

Reproductive Health Needs Among Substance Use Disorder Treatment Clients.

Terplan M, Lawental M, Connah MB, Martin CE.

J Addict Med. 2016 Jan-Feb;10(1):20-5. doi: 10.1097/ADM.0000000000000175.

PMID:
26690290
50.

Factors Associated with Early Pregnancy Smoking Status Among Low-Income Smokers.

Coleman-Cowger VH, Koszowski B, Rosenberry ZR, Terplan M.

Matern Child Health J. 2016 May;20(5):1054-60. doi: 10.1007/s10995-015-1891-y.

Supplemental Content

Loading ...
Support Center